The visual and anatomical improvements achieved after 6 monthly intravitreal doses of aflibercept were largely maintained over the second six months with as-needed dosing in patients with macular edema secondary to central retinal vein occlusion. Results: At week 52, the mean percentage of patients gaining ≥15 letters was 60.2% in the aflibercept group and 32.4% in the sham group (P = .0004). Aflibercept patients, compared with sham patients, had a significantly higher mean improvement in best-corrected visual acuity (+16.9 vs +3.8 letters, respectively) and reduction in central retinal thickness (-423.5 vs -219.3 µm, respectively) at week 52 (P < .0001 for both). Aflibercept patients received a mean (standard deviation) of 2.5 (1.7) injections during PRN dosing. The most common ocular adverse events in the aflibercept group were related to the injection procedure or the underlying disease and included macular edema (33.7%), increased intraocular pressure (17.3%), and eye pain (14.4%).
Main Outcome Measures:
The primary efficacy endpoint was the proportion of patients who gained ≥ 15 letters in best-corrected visual acuity (BCVA) at week 24. This study reports week-52 results including the proportion of patients who gained ≥ 15 letters in BCVA and the mean change from baseline BCVA and central retinal thickness (CRT) . Efficacy endpoints at week 52 were all exploratory.
Results: At week 52, the mean percentage of patients gaining ≥15 letters was 60.2% in the aflibercept group and 32.4% in the sham group (P = .0004). Aflibercept patients, compared with sham patients, had a significantly higher mean improvement in best-corrected visual acuity (+16.9 vs +3.8 letters, respectively) and reduction in central retinal thickness (-423.5 vs -219.3 µm, respectively) at week 52 (P < .0001 for both). Aflibercept patients received a mean (standard deviation) of 2.5 (1.7) injections during PRN dosing. The most common ocular adverse events in the aflibercept group were related to the injection procedure or the underlying disease and included macular edema (33.7%), increased intraocular pressure (17.3%), and eye pain (14.4%).
Conclusions:
Treatment with intravitreal aflibercept provided significant functional and anatomical benefits after 52 weeks as compared with sham. The improvements achieved after 6 Page 5 of 28 monthly doses at week 24 were largely maintained until week 52 with as-needed dosing.
Intravitreal aflibercept was generally well tolerated.
INTRODUCTION
The most common cause of vision loss in patients with central retinal vein occlusion (CRVO) is macular edema, which resolves spontaneously in only 30% of non-ischemic cases, and may not resolve in ischemic cases. 1, 2 Several lines of evidence indicate that vascular endothelial growth factor (VEGF) may play a key role in the pathophysiology of macular edema secondary to CRVO. VEGF is released in response to retinal hypoxia, which occurs in CRVO due to impaired capillary blood flow. 3 VEGF stimulates angiogenesis, and may result in neovascularization of the retina and/or the anterior segment, as well as vascular leakage resulting in macular edema. 3 In CRVO patients, the vitreous level of VEGF correlates with the severity of macular edema. 4 Furthermore, intravitreal injections of the anti-VEGF agents, ranibizumab or aflibercept, significantly improve visual and anatomical outcomes in patients with macular edema secondary to CRVO.
5-9
Intravitreal aflibercept (historically known in the scientific literature as VEGF Trap-Eye
[VTE]; Regeneron Pharmaceuticals, Inc.; Tarrytown, NY, USA, and Bayer Healthcare Pharmaceuticals, Berlin, Germany) is a fusion protein of key domains from human VEGF receptors 1 and 2 with human IgG Fc that binds to multiple VEGF-A isoforms with a higher affinity than ranibizumab and bevacizumab. 10 Studies of intravitreal aflibercept injections in patients with neovascular age-related macular degeneration (AMD) demonstrated that aflibercept given monthly for three initial administrations and then once every two months improves visual and anatomical outcomes as effectively and safely as monthly ranibizumab over a one-year period. 11 The efficacy and safety of intravitreal aflibercept for the treatment of macular edema secondary to CRVO was investigated in two parallel trials performed in Europe and Asia/Pacific (GALILEO) and in the US (COPERNICUS). 5, 7, 9 The primary efficacy endpoint of the GALILEO study was at week 24 and was published previously. 9 Here we report the 52-week results of the GALILEO study.
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METHODS
Study Design
The GALILEO study is an 18-month, randomized, double-masked, phase 3 study comparing the efficacy and safety of intravitreal aflibercept with sham for the treatment of macular edema secondary to CRVO. The study protocol was approved by the institutional review board or ethics committee at each site. All patients signed a written consent form before initiation of the study-specific procedures. The study was registered with ClinicalTrials.gov The design and eligibility criteria for the GALILEO study have previously been described. 9 Only one eye from each patient was included in the study. Patients were randomized in a 3:2 ratio to receive 2 mg intravitreal aflibercept (IVT-AFL 2Q4) or sham injections in the study eye once every 4 weeks for 20 weeks, for a total of 6 doses ( Figure 1 ).
From week 24 to week 52, patients in the aflibercept group were evaluated monthly and anterior segment, optic disc, or elsewhere in fundus. Given that there was no approved treatment for CRVO when the GALILEO study was designed, no other rescue treatment was prespecified. The GALILEO study design included a full year treatment with sham based on the request from health authorities. However, considering this long duration of sham treatment, the visual acuity and other ocular findings were carefully monitored by a team of masked medical reviewers. If, at any time, this review team had the impression that a patient might not benefit from further study participation or might be more adequately treated outside the study, the investigator was queried and asked to provide a re-assessment of the patient. Investigators then used their medical judgment to ultimately determine whether it would still be beneficial for the patient to continue the study.
Outcome Measures
The primary efficacy endpoint of the GALILEO study was the proportion of patients achieving a gain of ≥ 15 letters in BCVA from baseline to week 24, which was published previously. 9 Here we report the 52-week results of the GALILEO study. Efficacy endpoints at week 52 were all exploratory and included the proportion of patients who gained ≥ 15 letters in BCVA, mean change from baseline BCVA and CRT, proportion of patients progressing to neovascularization of the anterior segment, optic disc, or elsewhere in the fundus, and change from baseline in the mean National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) total and subscale (distance activities, near activities, and vision dependency) scores.
The efficacy and safety endpoints were assessed as described previously. 9 BCVA and CRT were assessed at baseline and every 4 weeks afterwards to week 52. Fundus weeks 24 and 52 using the NEI VFQ-25, which was administered by masked site personnel prior to intravitreal injections.
Statistical Analyses
The efficacy endpoints were analyzed in the full analysis set (FAS), which included all randomized patients who received any study treatment and had a baseline and at least one post-baseline BCVA assessment. In a prespecified analysis of proportions of patients who gained ≥ 15 letters at week 24 (the primary efficacy endpoint), patients who discontinued before week 24 were considered as non-responders. In a prespecified analysis of proportions of patients who gained ≥ 15 letters at week 52, the missing values were imputed by the lastobservation-carried-forward (LOCF) method. Between-group differences in the proportion of patients who gained ≥ 15 letters were evaluated with a 2-sided Cochran-Mantel-Haenszel test.
Continuous variables were analyzed with an analysis of covariance, except for BCVA, which was assessed using an analysis of variance. LOCF approach was used to impute missing values. For sensitivity, additional analyses were performed using observed values at week 52. The proportion of patients developing neovascularization by week 52 was analyzed using a Cochran-Mantel-Haenszel test. Safety from baseline to week 24 was analyzed in the safety analysis set, which included all randomized patients who received any study treatment.
Safety from week 24 to 52 was analyzed in week 24 completers within safety analysis set.
RESULTS
Of 240 patients screened, 106 patients were randomized to the IVT-AFL 2Q4 + PRN 
Visual outcomes
At week 24, the proportion of patients who gained ≥ 15 letters in BCVA was 60.2% and 22.1% in the IVT-AFL 2Q4 and sham groups, respectively (patients who discontinued before week 24 were considered as non-responders; P < .0001). 9 At week 52, the proportion of patients who gained ≥ 15 letters in BCVA was 60.2% in the IVT-AFL 2Q4 + PRN group versus Page 11 of 28 32.4% in the sham group (LOCF; Figure 2A ). More patients in the sham group had ≥ 15 letters of improvement in BCVA at week 52 compared with week 24 (32.4% vs 22.1%, respectively).
At week 52, patients treated with IVT-AFL 2Q4 + PRN maintained the improvements in BCVA achieved at week 24.
The proportion of patients who gained ≥ 10 and ≥ 30 letters or those who lost > 0, > 10, and > 15 letters at week 52 are shown in Table 1 . Overall, higher proportions of sham patients lost > 0, > 10, and > 15 letters compared with patients treated with IVT-AFL 2Q4 + PRN at week 52 ( Table 1 ).
The mean change from baseline BCVA in the IVT-AFL 2Q4 + PRN and sham groups was 18.0 versus 3.3 letters at week 24 and 16.9 versus 3.8 letters at week 52 (P < .0001 for both; Figure 2B 
Anatomical Outcomes
At week 24, the mean CRT reduction from baseline was 448. 
Patient-Reported Outcomes
A clinically relevant improvement in the mean NEI VFQ-25 total score (≥ 4-point increase) was observed in both IVT-AFL 2Q4 + PRN (7.8 points) and sham (4.5 points) groups at week 52 ( Table 2 ). The mean change from baseline to week 52 in near activities subscore was the highest among subscales, with IVT-AFL 2Q4 + PRN patients reporting a mean change of 12.2 points versus sham patients reporting a mean change of 5.0 points. No difference was noted between the two groups in the dependency subscale.
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Study Drug Injections
During the 52 weeks of treatment, the mean (± SD) number of injections was 11.8 ± 2. to 52, with a mean ± SD of 2.5 ± 1.7 injections during the PRN phase of study (Table 3) .
Patients who received ≤ 3 PRN injections had relatively higher BCVA gains than those who received 4-6 injections ( Table 3 ). The median time (95% CI) to the first PRN intravitreal aflibercept injection was 83 days (62 to 88 days).
Safety
The percentage of patients experiencing at least one ocular treatment-emergent adverse event (TEAE) in the sham and intravitreal aflibercept groups was 64.7% and 54.8% from baseline to week 24, and 50.9% and 69.1% from week 24 to week 52, respectively. The most common ocular TEAEs reported for the study eye in the intravitreal aflibercept group as compared with the sham group were eye pain (11.5% vs 4.4%, respectively), increased intraocular pressure (IOP) (8.7% vs 5.9%, respectively), and conjunctival hemorrhage (8.7% vs 4.4%, respectively) from baseline to week 24, and worsening of macular edema (35.1% vs 10.5%, respectively), increased IOP (13.4% vs 3.5%, respectively), and reduced visual acuity (11.3% vs 1.8%, respectively) from week 24 to week 52. All adverse events of IOP elevation were mild, except for one severe event, which occurred in a sham patient before week 24.
Ocular treatment-emergent serious adverse events (SAEs) are shown in Table 4 . Most ocular SAEs were related to the disease state or injection procedure, and there were no clinically relevant differences between the treatment groups in terms of frequency or pattern of SAEs.
The incidence of non-ocular TEAEs was similar in the sham and intravitreal aflibercept groups from both baseline to week 24 (54.4% and 45.2%, respectively), and week 24 to week Page 14 of 28 52 (50.9% vs 51.5%, respectively). Nasopharyngitis was the most commonly reported nonocular TEAE in both sham and intravitreal aflibercept groups from both baseline to week 24 (8.8% vs 7.7%, respectively) and week 24 to week 52 (19.3% vs 9.3%). Non-ocular SAEs occurred in a small group of patients with a similar frequency in both sham and intravitreal aflibercept groups from baseline to week 24 (7.4% and 5.8%, respectively) and week 24 to week 52 (8.8% and 6.2%, respectively). None of the non-ocular SAEs were reported for more than one patient from baseline to week 24. During weeks 24 to 52, non-ocular SAEs reported for more than one patient were pneumonia (one patient in each treatment group), and syncope (two patients in the sham group and one patient in the aflibercept group). No adverse event was adjudicated as an Anti-Platelet Trialists' Collaboration (APTC)-defined arterial thromboembolic event during the course of study. There were no deaths during the 52 weeks of this study.
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DISCUSSION
The findings of the current study demonstrate that the improvements in BCVA and CRT achieved with monthly intravitreal aflibercept injections in the first 24 weeks of treatment were largely maintained during the PRN (as-needed) phase of study, with monthly monitoring and a mean of 2.5 injections from weeks 24 to 52. Of note, there was also a marked improvement in BCVA with aflibercept in a subgroup of patients with nonperfused retinas at baseline, in contrast to a particularly poor response in the sham group. The visual improvements with aflibercept enhanced vision-related quality of life, particularly in near visual activities. In this study, aflibercept was generally well tolerated, and most common adverse events were those typically associated with intravitreal injections or the underlying disease. The increase in macular edema seen in aflibercept patients during the PRN dosing phase suggests that some patients would have benefited from more regular dosing, rather than being treated in response to the recurrence of disease.
The sister study of GALILEO, the COPERNICUS study, demonstrated comparable improvements in BCVA and CRT with intravitreal aflibercept injections. 5, 7 However, the sham groups in the two studies were not comparable during weeks 24 to 52 because, in the COPERNICUS study, sham patients received aflibercept PRN starting from week 24 whereas, in the GALILEO study, sham patients continued to receive sham treatments through week 52.
In the COPERNICUS study, patients receiving sham + IVT-AFL PRN did not achieve visual and anatomical improvements as robustly as those receiving aflibercept from the inclusion at week 52, suggesting that patients with macular edema secondary to CRVO may benefit from initiating treatment early with aflibercept. 7 Treatment of CRVO with monthly intravitreal injections for 6 months, followed by monthly monitoring and PRN injections for an additional 6 months has been studied for ranibizumab in the CRUISE trial. 8 Visual and anatomical outcomes reported from the CRUISE study are comparable to those from the COPERNICUS and GALILEO studies, with gains achieved during Page 16 of 28 the fixed monthly dosing phase largely maintained under PRN dosing with monthly monitoring. 8, 13 However, it is suggestive that the steeper decline in visual acuity between months 6 and 7 with 0.5 mg ranibizumab in the CRUISE study, compared with the smaller decline seen with aflibercept during the same time period in the GALILEO study, is reflective of a longer duration of effect with aflibercept.
The GALILEO results at week 52 corroborate the robust effect on visual and anatomical measures seen at week 24 in patients with macular edema secondary to CRVO, after 24 weeks of fixed monthly dosing with aflibercept. Originally, the PRN dosing regimen was introduced to investigate the feasibility of extending the treatment interval after the initial monthly aflibercept (.3423) a n = 65 for sham and n = 96 for IVT-AFL 2Q4.
b n = 67 for sham and n = 97 for IVT-AFL 2Q4 + PRN (except for the total score, which was n = 98). CI = confidence interval; IVT-AFL 2Q4 = intravitreal aflibercept injection monthly from baseline to week 24; IVT-AFL 2Q4 + PRN = intravitreal aflibercept injection monthly from baseline to week 24 and PRN from week 24 to week 52; LS = least square.
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